Management of systemic candidal infections in the intensive care unit

American Journal of Health-System Pharmacy

Volumn 59, Issue 1, 2002, Pages 33-41

  Kam, Linda W ^a   Lin, Jason D ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Amphotericin B; Antifungals; Candidiasis; Critical illness; Fluconazole; Hospitals; Itraconazole; Ketoconazole; Toxicity

Indexed keywords

2 HYDROXYPROPYL BETA CYCLODEXTRIN; AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; CASPOFUNGIN; ECHINOCANDIN B DERIVATIVE; FLUCONAZOLE; HYDROXYITRACONAZOLE; ITRACONAZOLE; KETOCONAZOLE; POSACONAZOLE; PROPYLENE GLYCOL; PYRROLE DERIVATIVE; VORICONAZOLE;

ABDOMINAL SURGERY; ANTIBIOTIC THERAPY; CANDIDA; CANDIDIASIS; CLINICAL TRIAL; CRITICAL ILLNESS; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG INDUCED DISEASE; FUNGEMIA; HIGH RISK PATIENT; HUMAN; IMMUNE DEFICIENCY; INTENSIVE CARE UNIT; LENGTH OF STAY; MORTALITY; NEPHROTOXICITY; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SYSTEMIC DISEASE;

EID: 0036239145     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/59.1.33     Document Type: Review

References (40)

1. National surveillance of nosocomial blood stream infection due to Candida albicans: Frequency of occurrence and antifungal susceptibility in the SCOPE program
2. The impact of candidernia on length of hospital stay, outcome, and overall cost of illness
3. Epidemiology of invasive mycosis in ICU patients: A prospective multicenter study in 435 non-neutropenic patients
4. Candida sepsis in surgical patients
5. The effect of empiric and prophylactic treatment with fluconazole on yeast isolates in a surgical trauma intensive care unit
6. The fluconazole era: Management of hematogenously disseminated candidiasis in the nonneutropenic patient
7. The prevalence of nosocomial infection in intensive care units in Europe: Results of the European Prevalence of Infection in Intensive Care (EPIC) study
8. The epidemiology of candidemia in two United States cities: Results of a population-based active surveillance
9. Epidemiology, diagnosis, and therapy of fungal infections in surgery
10. Nosocomial Candida. Epidemiology, transmission, and prevention
11. Risk factors for hospital acquired candidemia
12. International conference for the development of a consensus on the management and prevention of severe candidal infections
13. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation
14. Emerging evidence of selection of fluconazole-tolerant fungi in surgical intensive care units
15. The changing face of candidemia: Emergence of non-Candida albicans species and antifungal resistance
16. Fluconazole prophylaxis prevents intraabdominal candidiasis in high-risk surgical patients
17. Antifungal agents. Part I. Amphotericin B preparations and flucytosine
18. Lipid-based amphotericin B for the treatment of fungal infections
19. Antileishmanial activity of amphotericin and other antifungal agents entrapped in liposomes
20. Amphotericin B lipid complex (ABLC): A molecular rationale for the attenuation of amphotericin B related toxicities
21. Lipid formulations of amphotericin B: Recent progress and future directions
22. Comparison of the activity of free and liposomal amphotericin B in vitro and in a model of systemic and localized murine candidiasis
23. Pharmacokinetics of liposomal amphotericin B (Ambisome) in critically ill patients
24. Comparison of the toxicity of amphotericin B in 5% dextrose with that of amphotericin B in fat emulsion in a randomized trial with cancer patients
25. Amphotericin B in lipid emulsion: Stability, compatibility, and in vitro antifungal activity
26. In vitro activity of voriconazole against Candida species
27. Isolation and in vitro susceptibility to amphotericin B, itraconazole and posaconazole of voriconazole-resistant laboratory isolates of Aspergillus fumigatus
28. Antifungal peptides: Novel therapeutic compounds against emerging pathogens
29. The significance of candidemia
30. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia
31. Intravascular catheter exchange and duration of candidemia
32. Therapeutic approaches in patients with candidemia. Evaluation in a multicenter, prospective, observational-study
33. Comparative study of the efficacy of fluconazole versus amphotericin B/flucytosine in surgical patients with systemic mycoses
34. A randomized study comparing fluconazole with amphotericin B/5-flucytosine for the treatment of systemic Candida infections in intensive care patients
35. Value of high dosage fluconazole in therapy of Candida infections in intensive care medicine